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ABSTRACT: The host- and bacteria-derived extracellular
polysaccharide coating of the lung is a considerable challenge
in chronic respiratory disease and is a powerful barrier to
eﬀective drug delivery. A low molecular weight 12−15-mer
alginate oligosaccharide (OligoG CF-5/20), derived from
plant biopolymers, was shown to modulate the polyanionic
components of this coating. Molecular modeling and Fourier
transform infrared spectroscopy demonstrated binding be-
tween OligoG CF-5/20 and respiratory mucins. Ex vivo studies
showed binding induced alterations in mucin surface charge
and porosity of the three-dimensional mucin networks in cystic ﬁbrosis (CF) sputum. Human studies showed that OligoG
CF-5/20 is safe for inhalation in CF patients with eﬀective lung deposition and modiﬁes the viscoelasticity of CF-sputum. OligoG
CF-5/20 is the ﬁrst inhaled polymer therapy, represents a novel mechanism of action and therapeutic approach for the treatment
of chronic respiratory disease, and is currently in Phase IIb clinical trials for the treatment of CF.
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1. INTRODUCTION
Chronic respiratory diseases are a major world health issue,
with >100 million people aﬀected, and are estimated to cause 4
million premature deaths annually.1 The polymeric, extrac-
ellular surface-coating of the lung represents an important
therapeutic target in both the treatment of respiratory disease
and also in therapeutic delivery of bioactive agents/therapies.2
In the diseased lung, the surface epithelia are coated with a
complex mucus layer composed of mucins, bacterial bioﬁlms
(containing extracellular polysaccharide (EPS) and high-
molecular weight (Mw) extracellular DNA (eDNA)), inﬂam-
matory cells, and keratinocytes (Figure 1a−c).3,4 Mucins are a
family of 19 polydisperse (250 kDa), heavily glycosylated block
copolymers, which are secreted into the mucus layer by
specialized epithelial cells that line the aero-digestive and
reproductive tracts (Figure 1a−c). Mucins play an important
role in innate immunity (as a functional barrier to pathogens
and environmental particulates) and epithelial homeostasis
(preventing water loss).5
In many chronic respiratory diseases, such as chronic
obstructive pulmonary disease (COPD) and cystic ﬁbrosis
(CF), the production of highly viscous/elastic mucus impedes
clearance and prolongs infection and airway inﬂammation.3,6 In
CF, the diﬃculties of targeting therapies to the epithelial lung
surface across this “mucus barrier” are compounded by the
presence of bacterial bioﬁlms on the surface of the epithelia.7
These bioﬁlms often contain multidrug resistant (MDR)
mucoid bacteria (e.g., Pseudomonas and Burkholderia spp.),
which secrete polyanionic (high Mw) EPS. The presence of
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these microorganisms, their bioﬁlm structure, and their
resistance to conventional antimicrobial/antibiotic therapy is
associated with higher morbidity/mortality.8 In chronic
respiratory disease, numerous approaches including nano-
particle- and nanocarrier-based systems have been described
in vitro in attempts to modify the structure of mucus and
sputum.9−11 Previous studies have identiﬁed the potential of
low Mw alginates to alter the rheological properties of the
mucus viscoelastic barrier.12
Alginate is a biopolymer found in marine algae and bacterial
EPS of C-5 epimer guluronic (G) and (1−4)-linked
mannuronic (M) acid. Alginates occur in nature as polydisperse
high Mw polymers (300−500 kDa), which, following chemical
or enzymatic hydrolysis, have been extensively employed in
food and biomedical applications (e.g as gelling agents and
wound-dressing materials). The ability to engineer alginate
oligomers of deﬁned G-M composition and size/degree of
polymerization (DPn) has allowed their development for
distinct biological applications.13 Previous in vitro studies
demonstrated that low Mw alginate oligomers (DPn = 10−
12; containing >85% G) could alter mucin/alginate and mucin/
DNA interactions at concentrations as low as 1.4 μg/mL12,14
and alter the structure of mucin by increasing pore-size, thereby
facilitating improved nanoparticle diﬀusion through the mucus
layer.15 Interestingly, in vitro studies have also demonstrated the
ability of OligoG CF-5/20 (Figure 1d; Mw 2600 Da, > 85% G
residues) to potentiate the action of antibiotics against MDR
CF pathogens (including Pseudomonas and Burkholderia
spp.),16−19 and in the case of the MDR P. aeruginosa
NH57388A in vivo.20
These initial studies, therefore, highlighted the potential of
oligomeric structures, based on G-alginate residues, as a
treatment in chronic lung disease (e.g., CF). We hypothesized
that when inhaled, these low Mw alginate oligosaccharides
could interact with (and modify) the structural assembly and
rheological properties of mucus (and sputum) in patients with
respiratory disease. Initial studies of this potential interaction
were undertaken using molecular modeling and Fourier
transform infrared spectroscopy (FTIR). Direct imaging and
electrophoretic light-scattering (ELS) were then utilized to
demonstrate how OligoG CF-5/20 induced the disruption of
respiratory mucin networks. Preclinical animal and human
studies showed that OligoG CF-5/20 is safe for delivery via an
inhaled route in the diseased lung, and this was tested in
healthy human Phase I and in CF patients in Phase IIa studies.
Further, the potential eﬀect of OligoG CF-5/20 in the
management of patients with chronic lung disease was studied
by investigating its ability to modify the rheological properties
of sputum from a series of CF patients.
2. EXPERIMENTAL SECTION
2.1. Preparation of Alginate Biomaterials. Alginate
oligosaccharide, OligoG CF-5/20 (>85% guluronic acid
content; Mw 2600 Da), was derived from the stem of brown
seaweed Laminaria hyperborea as previously described.16
2.2. Molecular Dynamic (MD) Studies of Mucin−
OligoG CF-5/20 Interactions. MD simulations were run on
the High Performance Wales Supercomputer (www.hpcwales.
co.uk; Supporting Information) using the predominant mucin
in the lung (MUC5AC) and taking into account the levels of
mucin glycosylation observed in the CF lung. A G-rich alginate
molecule of 12 DPn length was utilized to represent OligoG
CF-5/20 at a ratio of 100 amino acids to 1 OligoG chain.
2.3. FTIR Spectroscopy of Mucin−OligoG CF-5/20
Interactions. Untreated control sputum samples from the
Phase IIa studies were thawed on ice and glycoprotein-
enrichment performed using high-speed, density gradient
centrifugation and guanidinium treatment of the gel-phase to
enrich the MUC5AC and MUC5B component.21 Samples were
then treated with 10% (v/v) distilled water ± 0.2% OligoG CF-
5/20 (w/v) and incubated statically at 37 °C for 60 min
(Supporting Information) prior to FTIR analysis.
2.4. Extraction of Pig Gastric Mucin. Mucin was
prepared and puriﬁed under nondenaturing conditions as
previously described22 and used in all the following studies.
2.5. Scanning Electron Microscopy (SEM) Imaging of
Pig Gastric Mucin. Pig gastric mucin (PGM; 0.2%) was
dissolved in distilled water and placed on a roller at 37 °C for 2
h prior to being ﬁlter sterilized. PGM samples ± 0.2% (1:1) or
2% (1:10) OligoG CF-5/20 (PGM/OligoG, respectively) were
placed onto Thermanox glass slides (Agar Scientiﬁc) in a 12-
well plate (Grenier Bio-One) and incubated at 37 °C for 1 h
statically before being ﬁxed overnight in 2.5% glutaraldehyde
(TAAB Laboratories). Samples were then washed with distilled
Figure 1. Respiratory disease and polymer therapy. (a) Diagram of the respiratory tract. (b) The ultrastructure of the lung epithelium. (c) Various
components of the mucus layer. (d) Structures of α-L-guluronate (G) and β-D-mannuronate (M); OligoG CF-5/20 has at least 85% of the monomer
residues as G residues.
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water (four times) and freeze-dried prior to imaging using a
Hitachi S4800 scanning electron microscope without sputter-
coating.
2.6. Atomic Force Microscopy Imaging of Pig Gastric
Mucin. PGM (0.004%) ± OligoG CF-5/20 (0.001%) was
dissolved in distilled water (4:1, PGM/OligoG) and a 1 μL
droplet placed on a freshly cleaved mica plate (Agar Scientiﬁc)
and left to air-dry. The concentration of OligoG CF-5/20 and
PGM was signiﬁcantly reduced in these studies where the
higher in vitro testing concentrations of OligoG CF-5/20
masked the results at the nanoscale level (Supporting
Information, Figure 1). Atomic force microscopy (AFM)
imaging was carried out on a Dimension 3100 AFM (Veeco)
over a 5 μm2 area (n = 6). AFM images were analyzed by
ImageJ software.
2.7. Electrophoretic Light Scattering of Pig Gastric
Mucin−OligoG CF-5/20 Interactions (Surface Charge). At
low concentrations, the zeta-potential of the OligoG CF-5/20-
only control (at both pH 5 and 7) was undetectable. Therefore,
in these experiments, the concentrations of OligoG CF-5/20
and the OligoG CF-5/20:PGM ratio was reduced to visualize
the mucin−oligomer interactions, which allowed the change in
mucin surface charge to be detected without “masking” by
OligoG CF-5/20. PGM (0.03%) ± OligoG CF-5/20 (0.02%)
was made up in NaCl buﬀer (0.001 M) at pH 5 and pH 7 (3:2,
PGM/OligoG) and ﬁlter sterilized (0.22 μm). Samples were
incubated at room temperature for 20 min prior to electro-
phoretic light scattering (ELS) analysis as previously
described.17 A Zetasizer Nano ZS (Malvern Instruments) and
disposable capillary cells (DTS1061) were used for the zeta
potential analysis. Electrophoretic mobility of samples was
analyzed using Smoluchowski’s equation.23
2.8. ImageJ Analysis of AFM and SEM Images. AFM
images of PGM were converted into binary mode and the
percentage area covered analyzed. SEM images of CF sputum
samples were enhanced prior to adjustment of threshold to
highlight dark porous areas within the images. These were then
converted into binary mode to allow measurement of surface-
area coverage.
2.9. Patients and Samples. Noninduced sputum samples
(n = 23) were collected by expectoration from seven patients
with CF attending the Cystic Fibrosis Service, Cardiﬀ and Vale
University Health Board (Supporting Information Table 1;
Ethics number: 11/WA/0318). Mean patient age was 26 years
(range 17−39), and mean forced expiratory volume in 1 s
(FEV1) was 0.80−1.93 L (46% of the predicted value; range
20−65%).
2.10. SEM Imaging of CF Sputum. Noninduced sputum
samples (0.1 mL) were incubated following treatments with
water (control), 100 nM rhDNase I (Pulmozyme; Genentech
Inc.), OligoG CF-5/20 (0.2% or 2%), or 100 nM rhDNase I ±
OligoG CF-5/20 (0.2, 2%) for 20 min (as previously
described24) at 37 °C. Nonhomogenized CF sputum samples
(0.1 mL) were then placed on freshly cleaved mica plates (Agar
Scientiﬁc) and left for 5−10 min to air-dry. Nonadherent
sputum was washed from the slides using PBS (pH 7.4). The
slides were then ﬁxed in 1 mL of 2.5% glutaraldehyde in a
sterile 12-well plate (24 h). Drying of the samples was achieved
via the ethanol dehydration method24 and imaging performed
using an Hitachi S4800 SEM without sputter coating.
2.11. Animal and Human Inhalation Studies. Animal
toxicity studies with OligoG CF-5/20 were performed in
Sprague−Dawley rats. See Supporting Information.
The human Phase I study was a single center, randomized,
placebo controlled, 72 h, dose escalation study to test the in
vivo safety and tolerability of OligoG CF-5/20 in humans
(www.clinicaltrials.gov, Identiﬁer: NCT00970346), and the
phase II study was a multicenter randomized placebo controlled
crossover study with 28 days treatment periods (www.
clinicaltrials.gov, Identiﬁer: NCT01465529). See Supporting
Information.
2.12. Scintigraphy Studies Were Conducted To
Investigate Lung Deposition of Radiolabeled OligoG.
For this, an open label two-way randomized crossover study in
10 CF patients was conducted (www.clinicaltrials.gov, Identi-
ﬁer: NCT01991028). See Supporting Information.
2.13. Rheological Analysis of CF Sputum. Noninduced
sputum from CF patients (Supporting Information, Table 1)
was collected and studied following written, informed consent
and study approval by the Local Research Ethics Committee
(11/WA/0318). Initial observational studies demonstrated that
2% OligoG CF-5/20 induced diﬀerences in the extensional
thinning behavior of CF sputum (Supporting Information,
Video 1). Due to the large heterogeneity found within sputum
samples, bulk rheology was subsequently carried out and
quantiﬁed using dynamic shear rheometry (Supporting
Information).
3. RESULTS
3.1. Predicting Molecular Interactions between
Guluronate Alginate Oligosaccharides and Mucin in CF
Sputum. MD modeling was initially utilized to provide
information on potential molecular interactions between
OligoG CF-5/20 and mucin (Supporting Information, Tables
2−8).25 MD modeling techniques were employed to study the
interaction of 12-mer guluronate oligosaccharides with a
glycosylated 100 amino acid sequence of the central motif of
MUC5AC (the predominant human airway mucin).26 The
glycan structures on the MUC5AC model peptide backbone
were core one and two glycan structures: core 1 (consisting of
N-acetylgalactosamine [GalNAc] and glucose) and core 2
(consisting of GalNAc, glucose, and N-acetyl-D-glucosamine
[GlcNAac]). These studies predicted binding of the guluronate
alginate oligosaccharide to both glycan structures and the
peptide backbone of the MUC5AC amino acid structure.
Speciﬁcally, bonding was found between the hydroxyl groups in
the G-alginate oligosaccharide and N- or O-atoms on the
peptide backbone; N-atoms from the amide group in GalNAc
and hydroxyl groups in the sugar rings constituting all
components of the glycan structures. This resulted in decreased
ﬂexibility and linearization of the local region of the MUC5AC
molecule (P = 0.0009; Figure 2a,b).
To determine whether this predicted mucin binding was
evident in vivo, attenuated total reﬂection-Fourier transform
infrared spectroscopy (ATR-FTIR) was used to characterize
the electrostatic interactions between the mucins and the
OligoG CF-5/20. CF sputum was obtained (www.clinicaltrials.
gov, Identiﬁer: NCT01465529) with written, informed consent
and following study approval by the Local Research Ethics
Committee (10/H1005/88). Absorbance spectra showed the
distinct peak positions of mucin and OligoG CF-5/20 (Figure
3a); the interaction between mucin and OligoG CF-5/20 was
evident in the Amide I region of the second-derivative spectra,
involving the carbonyl group within the peptide link of the
mucin protein backbone (Figure 3b). Post-treatment, absorb-
ance was decreased at the random coil associated wavenumber
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1652 cm−1 and β-sheet associated wavenumber 1637 cm−1,
with a shift in peak positions to higher frequencies at 1650 and
1634 cm−1 as previously described27 (www.r-project.org). FTIR
analysis predicted widespread H+-bonding between the
oligosaccharide and peptide, leading to reduced ﬂexibility of
the mucin molecule post-treatment, as predicted by the MD
studies.
3.2. OligoG CF-5/20 Modulation of the Surface
Charge and Structural Assembly of Mucin Networks ex
Vivo. Following these initial results, the interaction of OligoG
CF-5/20 was directly observed ex vivo with porcine mucin
samples by employing AFM, SEM, and ELS to characterize the
surface charge using zeta potential analysis. PGM has been
extensively employed, and its biophysical features characterized
as a homologue of MUC5AC in previous studies.9,28−30
Furthermore, AFM imaging has been extensively utilized to
characterize mucin networks in vitro,23 investigating glyco-
protein structure and interactions.31
AFM imaging revealed that treatment with OligoG CF-5/20
signiﬁcantly modiﬁed the mucin network by changing its
morphology and causing increased pore size of the network
with a reduction in mucin interlinking networks. Unsurpris-
ingly, there was an increase in surface area due to the addition
of OligoG CF-5/20 (52.1%) into the system compared to the
control (28.8%) when analyzed using ImageJ (P < 0.0001;
Figure 4a). SEM showed that at 0.2% OligoG CF-5/20, there
appeared to be minimal eﬀect on porosity, with OligoG CF-5/
20 instead seeming to coat the surface of the mucin. At 2%,
however, OligoG CF-5/20 induced marked morphological
changes in the mucin networks with treated samples exhibiting
signiﬁcantly increased porosity compared to the control (Figure
4b). These in vitro structural changes reﬂected those predicted
by initial MD modeling and FTIR studies, with alterations in
bonding between mucin chains resulting in a more open mucin
network. ELS (zeta-potential) analysis also revealed that
treatment with OligoG CF-5/20 induced marked alterations
in mucin surface charge. Signiﬁcantly increased negative surface
charge of the mucin was evident after treatment with OligoG
CF-5/20 at 0.001 M NaCl, pH 5 (−16.0 mV vs −24.2 mV) and
pH 7 (−16.7 mV vs −23.1 mV) (P < 0.0001; Figure 5a,b).
Because of the low concentration of the OligoG CF-5/20-only
control (at pH 5 and 7), only multiple, weak unstable peaks
were seen conﬁrming the mucin−oligomer interaction. These
studies, therefore, conﬁrmed the ability of OligoG CF-5/20 to
modify both the surface charge and the structural assembly of
the mucin biopolymer.
3.3. Optimizing Chronic Pulmonary Administration of
the Polymer in the CF Lung. Preclinical animal and human
respiratory studies demonstrated that OligoG CF-5/20 could
be reliably and safely administered via inhalation to the lung.
Initial dose-escalation animal studies were undertaken for up to
28 days (with estimated achieved dose levels of 288−467 mg/
Figure 2. Molecular characterization of alginate-mucin interactions.
(a) A snapshot of the 10 ns mucin and OligoG CF-5/20 (dark blue)
simulation depicting the interactions that occur between the two. (b)
Root−mean−square deviation (RMSD) per residue for mucin (black)
and mucin with OligoG CF-5/20 (blue); the red squares indicate
hydrogen bonds between OligoG CF-5/20 and the mucin molecule.
The mean RMSD per residue is reduced from 1.15 to 0.99 Å when
OligoG CF-5/20 is introduced into the simulation. For residues where
OligoG CF-5/20 forms hydrogen bonds, the RMSD is reduced from
1.24 to 0.88 Å.
Figure 3. FTIR absorbance spectra showing diﬀerential peak positions between mucin (black) and mucin treated with 0.2% OligoG CF-5/20 (blue);
speciﬁcally a peak decrease at 1652 cm−1 and peak shifts at 1650 and 1634 cm−1 (OligoG CF-5/20 is shown for reference; red). (a) Original spectra.
(b) Enhanced view showing the second derivative spectra of the amide I region (1700−1600 cm−1).
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kg/day; Supporting Information, Tables 9−12). These
demonstrated no adverse clinical signs or test-item related
changes in body weight, food consumption, respiratory,
hematological, or biochemical parameters. A separate animal
study with tritiated OligoG CF-5/20 showed that following oral
administration of OligoG CF-5/20, the majority was excreted
via the gastrointestinal (GI) tract (82.6% within the ﬁrst 24 h).
Furthermore, intravenous administration of the 3H-labeled
OligoG CF-5/20 in animals revealed standard drug-like
properties with rapid elimination via urine (80.3% within the
ﬁrst 24 h).
A clinical Phase I study (Supporting Information, Table 13)
also demonstrated that inhalation of OligoG CF-5/20 (dosing
up to 540 mg/day over 3 days) was well-tolerated, with no
toxicity/adverse events or clinically signiﬁcant changes in
hematology, biochemistry, urinalysis, or vital signs (blood
pressure, pulse, respiration rate, body temperature, SpO2, ECG,
or spirometry) observed.
The administration of the agent OligoG CF-5/20 to the
diseased lung was planned as an inhalational therapy.32 A lung
scintigraphic study was, therefore, performed to characterize
the pulmonary deposition of 99mTc-labeled OligoG CF-5/20 in
both nebulized solution and as an inhaled, dry-powder
formulation in the diseased lungs of patients with CF. This
single-dose study demonstrated that both formulations were
well-tolerated. The dry-powder inhalation exhibited a signiﬁ-
cantly increased whole lung deposition compared to the
nebulized solution (38.6% vs 17.1%; P = 0.001; Figure 6a,b)
and a signiﬁcantly lower deposition in the oro-pharyngeal
(mouth, pharynx, and gastric) region (11.3% vs 19.9%; P =
0.033; Supporting Information, Table 14).
3.4. OligoG CF-5/20 Induced Disruption of the Mucin
Hydrogel Network of CF Sputum. The eﬀects of OligoG
CF-5/20 on patient sputum samples were studied ex vivo using
a combination of imaging and rheological analysis. These
experiments employed the OligoG CF-5/20 alone and in
combination with recombinant human rhDNase I (Pulmozyme,
a common mucolytic treatment employed in CF).33,34 SEM
Figure 4. Eﬀect of mucin−alginate interactions on polymer
morphology. (a) AFM imaging (5 μm) of PGM (0.004% PGM) ±
OligoG CF-5/20 (0.001%), z-scale 9 nm. (b) SEM imaging of PGM ±
0.2−2% OligoG CF-5/20, scale bar 5 μm.
Figure 5. Eﬀect of mucin−alginate interactions on surface charge. Zeta-potential measurements of PGM (0.03%; solid line) ± OligoG CF-5/20
(0.02%; dashed line) performed at 0.01 M NaCl (a) pH 5 and (b) pH 7.
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demonstrated the previously reported anisotropic (directional)
nature of the sputum with marked variation in pore-size (Figure
7a).24,35 The SEM results were, unsurprisingly, not as
pronounced as those observed in AFM analysis of PGM
alone due to the lack of contrast with the substratum, the lower
OligoG CF-5/20 concentration used (0.001%), and artifactual
contraction of the sample during freeze-drying.35 Treated
samples demonstrated a marked dose-dependent increase in
porosity when treated with OligoG CF-5/20 (Figure 7a), where
the diﬀerence in percentage surface area of pores between the
control (8.91 ± 4.49%) and 2% OligoG CF-5/20-treated
sputum (16.61 ± 3.00%) was signiﬁcantly diﬀerent (P = 0.007).
Interestingly, while DNase I alone demonstrated alteration in
the structure of sputum (in keeping with previous studies24),
marked increases in the porosity of CF sputum networks after
treatment with rhDNase I and the OligoG CF-5/20 were
evident. Imaging demonstrated synergy between OligoG CF-5/
20 and the rhDNase I in disrupting the three-dimensional
network of the sputum (Figure 7a).
3.5. OligoG CF-5/20 Induced Improvement of the
Viscous and Elastic Properties of CF Sputum. The ability
of OligoG CF-5/20 to modify the viscoelasticity of CF sputum
was tested using extensional and shear rheology. The studies
were performed using noninduced sputum from seven patients
(n = 23 samples; Supporting Information, Table 1). Initial
diﬀerences were observed in video imaging and extensional
rheology (Figure 7b), with OligoG CF-5/20 inducing rapid
“extensional thinning” behavior of CF sputum compared to the
control (Supporting Information, Video 1).
To analyze bulk changes, shear rheology was then utilized,
employing a frequency range of 0.1−10 Hz (relevant to
biological processes in the airway). The eﬀect of OligoG CF-5/
Figure 6. Deposition of OligoG CF-5/20 in the CF lung. (a) Deposition of a radio-labeled OligoG CF-5/20 DPI formulation (dry powder for
inhalation) in the lungs of a CF patient (a) anterior and (b) posterior view.
Figure 7. (a) SEM of CF sputum ±0.2% or 2% OligoG CF-5/20 ± rhDNase I (100 nM), scale bar 1 μm. (b) Extensional rheology illustration of the
physical properties of CF sputum (images taken at 250 frames per second, fps).
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20 at a range of concentrations (0.2−2%) on CF sputum
samples was compared to those of distilled water (Figure 8a)
and rhDNase I controls (Figure 8b, 9a,b). Ionic strength
variations were minimized by preparing all samples in distilled
water. OligoG CF-5/20 treatment exhibited marked reductions
in both elastic (G′) and viscous response (G″) (Figure 8a) of
CF sputum compared to the water-treated control (0.16 Hz; P
< 0.0001). A signiﬁcant reduction in the elastic response, G′ (P
= 0.0005), and viscous response, G″ (P = 0.0175), was also
seen at 10 Hz (Supporting Information, Figure 2). To monitor
clinical reproducibility of potential changes in the eﬃcacy of
OligoG CF-5/20 with disease-state, a longitudinal study of
sputum rheology was also conducted using successive samples
(n = 9) from a single subject (receiving 7% hypertonic saline,
rhDNase I, and intravenous antibiotics). This patient
demonstrated marked intraindividual variation (at 0.16 Hz) in
control values of elastic response (Figure 9a) and viscous
response (Figure 9b), with marked heterogeneity in the
observed viscoelastic properties of their sputum. In these
experiments, samples were treated with rhDNase I (the
standard mucolytic treatment employed in CF clinical
practice33,36), and a ﬁnal rhDNase I concentration of 2.5 μg/
mL (approximately 100 nM) was chosen in accord with
previous studies.37 The distinct mechanism of action of
rhDNase I induces degradation of the large, viscous polyanionic
eDNA and subsequent changes in the viscoelasticity.37 In these
studies, samples treated with rhDNase I in conjunction with 2%
OligoG CF-5/20 showed statistically signiﬁcant diﬀerences in
both G′ (P = 0.004) and G″ (P = 0.001; Figure 8b). The
structural changes in CF sputum following OligoG CF-5/20
treatment were reﬂected in the ability of OligoG CF-5/20 to
modify the viscoelastic properties (G′ and G″) of CF sputum
with signiﬁcant, reproducible changes induced over the entire
frequency range.
4. DISCUSSION
These studies demonstrate that a novel oligosaccharide
polymer therapy38 from nature can disrupt mucin hydrogel
networks in sputum and represent a novel and highly safe
mechanistic approach in the treatment of chronic lung disease.
The initial MD modeling and FTIR results in this study
predicted the ability of a 12-mer G-block structure (based on
OligoG CF-5/20) to exhibit mucin-binding and demonstrated
how this binding might result in a reduction in the potential
sites of interaction with both mucin chains and molecules. The
subsequent in vitro studies (using AFM and SEM) went on to
demonstrate that this binding did induce physical disruption of
the glycoprotein-enriched, mucin polymer network. This
ﬁnding was potentially clinically important, as workers have
previously demonstrated that “branching” of CF mucin
(associated with increased glycosylation) impairs drug diﬀusion
in vitro.29
SEM previously has been used to investigate the eﬀects of
nanoparticle systems on mucin aggregation.15,39 Moreover,
these changes reﬂect recent ex vivo studies, which demonstrated
similar charge alterations in mucins when PGM was treated
with the heteropolysaccharide pectin.23 While the structural
changes observed here (in porosity and branching) are
Figure 8. Shear rheology analyses of CF sputum samples showing (a) changes in elastic response (G′) and viscous response (G″) of 2% OligoG CF-
5/20 treatment of sputum samples compared to water-treated controls (0.16 Hz; n = 23). (b) Longitudinal study for samples (n = 9) from a single
patient over 9 days showing shear rheology values (0.16 Hz) for various sputum treatments ±0.2%, 2% OligoG CF-5/20 and/or rhDNase I (100
nM).
Molecular Pharmaceutics Article
DOI: 10.1021/acs.molpharmaceut.5b00794
Mol. Pharmaceutics 2016, 13, 863−872
869
signiﬁcant, the ionic charge distribution of the mucin polymer
network is also a key determinant of penetration both in vitro
and in vivo.40 The ability of OligoG CF-5/20 to modify the
anionic surface-charge of the mucin was also important and
may explain the previously reported increase in mobility of
nanoparticle diﬀusion observed in low molecular weight
alginate-treated mucus.15 As the spatial arrangement of charge
and structural assembly within the mucin network is pivotally
important in determining the transport of materials in vivo,
these changes indicated that OligoG CF-5/20 may exhibit
clinically signiﬁcant eﬀects in modifying the mucus barrier in
the lungs in vivo.
A number of inhaled therapies have already been identiﬁed to
potentially modify mucus clearance and increase diﬀusion
through the mucin barrier for gene-, drug-, and protein-delivery,
employing both mucolytic and decreased muco-adhesive
approaches.41 Examples include rhDNase I, a mucolytic
showing high eﬃcacy in vivo in altering the viscoelasticity of
CF sputum,37 and hypertonic saline, which modiﬁes the
rheological properties of mucus and stimulates the cough
reﬂex.42 Safety is of pivotal importance, as a number of
theoretical nanomedicine approaches described in the literature
have been either ineﬀective in vivo or associated with side-
eﬀects or diﬃculty of use.42,43
As the in vitro experiments appeared promising, toxicity
studies were undertaken in vivo. The initial oral toxicity studies
demonstrated the relatively rapid excretion and lack of systemic
absorption of OligoG CF-5/20 (see Supporting Information).
Importantly, while OligoG CF-5/20 was eliminated via the GI
tract, these studies revealed no clinical evidence of modiﬁcation
of the GI mucin barrier even following chronic, high-dose
administration. The lack of toxicity was conﬁrmed in
subsequent Phase IIa human studies, which established the
safety of inhaled OligoG CF-5/20 in both healthy and
chronically diseased lungs.
The lack of safe nanomedicine-based inhalation therapies
that eﬃciently penetrate the mucin barrier gives the natural
oligomer, OligoG CF-5/20, an inherent advantage. These
toxicity and pharmaco-distribution studies demonstrated that
OligoG CF-5/20 could be delivered to the diseased CF lung at
doses that were deemed eﬀective in vitro. OligoG CF-5/20 has
been granted orphan status by the European Medicines Agency
(EU/3/07/475) for the treatment of CF. The lack of toxicity
for OligoG CF-5/20 was anticipated based on existing
knowledge of sodium alginate, which is registered in the
European Pharmacopoeia and US Pharmacopeia.
While the “simplistic” in vitro mucin studies were
encouraging, the sputum of the diseased lung is a highly
complex therapeutic target, being composed of <5% mucin,
>90% water, and containing variable amounts of polyanions
such as eDNA and EPS.44 Previous studies have shown that the
rheological changes induced by guluronate oligomers in the
treatment of CF sputum are the result of disruption in
interpolymer cross-links and not simply the result of varying
ionic strength.12 The marked heterogeneity in the elastic and
viscous properties of sputum samples in our longitudinal
observations from a single patient further highlight the
complexity of sputum as a therapeutic target. The predictable
decrease in the elastic and viscous responses of CF sputum,
which were observed when the results with OligoG CF-5/20
Figure 9. Longitudinal study of CF sputum samples obtained from a single patient over 9 days (AM, morning; PM, evening) showing change in (a)
elastic response, G′, and (b) viscous response, G″, at 0.16 Hz (compared to the untreated control) for sputum treatments ±2% OligoG CF-5/20 or
rhDNase I (100 nM).
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were compared with rhDNase I, reﬂected the universal
alteration in the structural assembly of mucus in OligoG CF-
5/20-treated CF sputum and its value as a therapeutic target.45
Importantly, for clinical utilization, these results showed that, in
these experiments, following OligoG CF-5/20 treatment, the
ratio of viscous to elastic response was maintained (the values
of G″ and G′ decreasing by similar proportions), allowing
optimum clearance of mucus by both cough and mucociliary
action.36,37 These studies, while important, were short-term
(<10 days) and are being extended in ongoing, longer term (28
days) Phase IIb clinical trials in CF patients (www.clinicaltrials.
gov, Identiﬁer: NCT02157922).
5. CONCLUSION
These studies highlight, at a nano- and macro-scale, the ability
of OligoG CF-5/20 to alter the structure of mucus, modulate
mucin assembly, and reduce the elastic and viscous properties
of sputum from CF patients and potentially other chronic
respiratory diseases. Employing such an approach may enable
physicians to utilize the high surface-area and noninvasive
nature of pulmonary administration34 to eﬀectively deliver
therapies across the mucin “barrier” in the treatment of a range
of human diseases. This study describes the ﬁrst-in-class of a
new generation of inhaled polymer therapies. It has clear
potential for the management of chronic lung disease such as
CF and oﬀers a novel mechanism to disrupt mucin hydrogel
networks in a range of other applications including drug
delivery and gene- and reproductive-therapy.
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